745 related articles for article (PubMed ID: 10873473)
21. YADD mutants of human immunodeficiency virus type 1 and Moloney murine leukemia virus reverse transcriptase are resistant to lamivudine triphosphate (3TCTP) in vitro.
Boyer PL; Gao HQ; Clark PK; Sarafianos SG; Arnold E; Hughes SH
J Virol; 2001 Jul; 75(14):6321-8. PubMed ID: 11413298
[TBL] [Abstract][Full Text] [Related]
22. A role for dNTP binding of human immunodeficiency virus type 1 reverse transcriptase in viral mutagenesis.
Weiss KK; Chen R; Skasko M; Reynolds HM; Lee K; Bambara RA; Mansky LM; Kim B
Biochemistry; 2004 Apr; 43(15):4490-500. PubMed ID: 15078095
[TBL] [Abstract][Full Text] [Related]
23. Outsmarting HIV drug resistance.
Balter M
Science; 1998 Nov; 282(5394):1623, 1625. PubMed ID: 9867659
[No Abstract] [Full Text] [Related]
24. Competitive capacity of HIV-1 strains carrying M184I or Y181I drug-resistant mutations.
Li J; Li L; Li HP; Zhuang DM; Liu SY; Liu YJ; Bao ZY; Wang Z; Li JY
Chin Med J (Engl); 2009 May; 122(9):1081-6. PubMed ID: 19493444
[TBL] [Abstract][Full Text] [Related]
25. Mechanistic studies comparing the incorporation of (+) and (-) isomers of 3TCTP by HIV-1 reverse transcriptase.
Feng JY; Anderson KS
Biochemistry; 1999 Jan; 38(1):55-63. PubMed ID: 9890882
[TBL] [Abstract][Full Text] [Related]
26. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques.
Ambrose Z; Boltz V; Palmer S; Coffin JM; Hughes SH; Kewalramani VN
J Virol; 2004 Dec; 78(24):13553-61. PubMed ID: 15564466
[TBL] [Abstract][Full Text] [Related]
27. Mutations at position 184 of human immunodeficiency virus type-1 reverse transcriptase affect virus titer and viral DNA synthesis.
Julias JG; Boyer PL; McWilliams MJ; Alvord WG; Hughes SH
Virology; 2004 Apr; 322(1):13-21. PubMed ID: 15063112
[TBL] [Abstract][Full Text] [Related]
28. The influence of 3TC resistance mutation M184I on the fidelity and error specificity of human immunodeficiency virus type 1 reverse transcriptase.
Rezende LF; Drosopoulos WC; Prasad VR
Nucleic Acids Res; 1998 Jun; 26(12):3066-72. PubMed ID: 9611256
[TBL] [Abstract][Full Text] [Related]
29. Investigating the "steric gate" of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by targeted insertion of unnatural amino acids.
Klarmann GJ; Eisenhauer BM; Zhang Y; Gotte M; Pata JD; Chatterjee DK; Hecht SM; Le Grice SF
Biochemistry; 2007 Feb; 46(8):2118-26. PubMed ID: 17274599
[TBL] [Abstract][Full Text] [Related]
30. Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors.
Ren J; Nichols C; Bird L; Chamberlain P; Weaver K; Short S; Stuart DI; Stammers DK
J Mol Biol; 2001 Sep; 312(4):795-805. PubMed ID: 11575933
[TBL] [Abstract][Full Text] [Related]
31. Mutational analysis of Lys65 of HIV-1 reverse transcriptase.
Sluis-Cremer N; Arion D; Kaushik N; Lim H; Parniak MA
Biochem J; 2000 May; 348 Pt 1(Pt 1):77-82. PubMed ID: 10794716
[TBL] [Abstract][Full Text] [Related]
32. Effects of mutations in the polymerase domain on the polymerase, RNase H and strand transfer activities of human immunodeficiency virus type 1 reverse transcriptase.
Gao HQ; Boyer PL; Arnold E; Hughes SH
J Mol Biol; 1998 Apr; 277(3):559-72. PubMed ID: 9533880
[TBL] [Abstract][Full Text] [Related]
33. Effect of a bound non-nucleoside RT inhibitor on the dynamics of wild-type and mutant HIV-1 reverse transcriptase.
Zhou Z; Madrid M; Evanseck JD; Madura JD
J Am Chem Soc; 2005 Dec; 127(49):17253-60. PubMed ID: 16332074
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus.
Trabaud MA; Leriche-Guerin K; Regis C; Bordes I; Cotte L; Detmer J; Kolberg J; Ritter J; Trépo C
J Med Virol; 2000 Jul; 61(3):352-9. PubMed ID: 10861645
[TBL] [Abstract][Full Text] [Related]
35. The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs.
Auwerx J; Van Nieuwenhove J; Rodríguez-Barrios F; de Castro S; Velázquez S; Ceccherini-Silberstein F; De Clercq E; Camarasa MJ; Perno CF; Gago F; Balzarini J
FEBS Lett; 2005 Apr; 579(11):2294-300. PubMed ID: 15848161
[TBL] [Abstract][Full Text] [Related]
36. Augmentation of human immunodeficiency virus type 1 subtype E (CRF01_AE) multiple-drug resistance by insertion of a foreign 11-amino-acid fragment into the reverse transcriptase.
Sato H; Tomita Y; Ebisawa K; Hachiya A; Shibamura K; Shiino T; Yang R; Tatsumi M; Gushi K; Umeyama H; Oka S; Takebe Y; Nagai Y
J Virol; 2001 Jun; 75(12):5604-13. PubMed ID: 11356968
[TBL] [Abstract][Full Text] [Related]
37. Nucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision.
Boyer PL; Sarafianos SG; Arnold E; Hughes SH
J Virol; 2002 Sep; 76(18):9143-51. PubMed ID: 12186898
[TBL] [Abstract][Full Text] [Related]
38. Identification of insertion mutations in HIV-1 reverse transcriptase causing multiple drug resistance to nucleoside analogue reverse transcriptase inhibitors.
Sugiura W; Matsuda M; Matsuda Z; Abumi H; Okano A; Oishi T; Moriya K; Yamamoto Y; Fukutake K; Mimaya J; Ajisawa A; Taki M; Yamada K; Nagai Y
J Hum Virol; 1999; 2(3):146-53. PubMed ID: 10413366
[TBL] [Abstract][Full Text] [Related]
39. Nucleotide analogue binding, catalysis and primer unblocking in the mechanisms of HIV-1 reverse transcriptase-mediated resistance to nucleoside analogues.
Selmi B; Deval J; Boretto J; Canard B
Antivir Ther; 2003 Apr; 8(2):143-54. PubMed ID: 12741627
[TBL] [Abstract][Full Text] [Related]
40. Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect.
Jeeninga RE; Keulen W; Boucher C; Sanders RW; Berkhout B
Virology; 2001 May; 283(2):294-305. PubMed ID: 11336554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
